Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects
Brief Summary: This is an Open-label Phase 3 study in adults with chronic genotypes 1, 2, 3, and 4 HCV infection who are co-infected with HIV-1.


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: ombitasvir/paritaprevir/ritonavir, Drug: ribavirin | Intervention Type: DRUG; Name: ombitasvir/paritaprevir/ritonavir; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D
B: Arm Label: 001 T(q8h) / PR; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Pegylated interferon alfa-2a, Drug: Telaprevir | Arm Label: 002 T(b.i.d.) / PR; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Telaprevir, Drug: Pegylated interferon alfa-2a | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 001 T(q8h) / PR, 002 T(b.i.d.) / PR | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): 002 T(b.i.d.) / PR | Intervention Type: DRUG; Name: Pegylated interferon alfa-2a; Assigned to Arm(s): 001 T(q8h) / PR, 002 T(b.i.d.) / PR | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): 001 T(q8h) / PR
C: Arm Label: Arm 1. PEG +RBV for 48 Wks (Part I); Type: ACTIVE_COMPARATOR; Interventions: Drug: peginterferon-alfa 2b (PegIntron), Drug: ribavirin | Arm Label: Arm 2. PEG + RBV + BOC for 28 Wks (Part I); Type: EXPERIMENTAL; Interventions: Drug: boceprevir (SCH 503034), Drug: peginterferon-alfa 2b (PegIntron), Drug: ribavirin | Arm Label: Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I); Type: EXPERIMENTAL; Interventions: Drug: boceprevir (SCH 503034), Drug: peginterferon-alfa 2b (PegIntron), Drug: ribavirin | Arm Label: Arm 4. PEG +RBV + BOC for 48 Wks (Part I); Type: EXPERIMENTAL; Interventions: Drug: boceprevir (SCH 503034), Drug: peginterferon-alfa 2b (PegIntron), Drug: ribavirin | Arm Label: Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I); Type: EXPERIMENTAL; Interventions: Drug: boceprevir (SCH 503034), Drug: peginterferon-alfa 2b (PegIntron), Drug: ribavirin | Arm Label: Arm 6. PEG + RBV + BOC for 48 Wks (Part II); Type: EXPERIMENTAL; Interventions: Drug: boceprevir (SCH 503034), Drug: peginterferon-alfa 2b (PegIntron), Drug: ribavirin | Arm Label: Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II); Type: EXPERIMENTAL; Interventions: Drug: boceprevir (SCH 503034), Drug: peginterferon-alfa 2b (PegIntron), Drug: ribavirin (low-dose) | Arm Label: Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I); Type: EXPERIMENTAL; Interventions: Drug: boceprevir (SCH 503034), Drug: peginterferon-alfa 2b (PegIntron), Drug: ribavirin | Intervention Type: DRUG; Name: boceprevir (SCH 503034); Assigned to Arm(s): Arm 2. PEG + RBV + BOC for 28 Wks (Part I), Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I), Arm 4. PEG +RBV + BOC for 48 Wks (Part I), Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I), Arm 6. PEG + RBV + BOC for 48 Wks (Part II), Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II), Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I) | Intervention Type: DRUG; Name: peginterferon-alfa 2b (PegIntron); Assigned to Arm(s): Arm 1. PEG +RBV for 48 Wks (Part I), Arm 2. PEG + RBV + BOC for 28 Wks (Part I), Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I), Arm 4. PEG +RBV + BOC for 48 Wks (Part I), Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I), Arm 6. PEG + RBV + BOC for 48 Wks (Part II), Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II), Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I) | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Arm 1. PEG +RBV for 48 Wks (Part I), Arm 2. PEG + RBV + BOC for 28 Wks (Part I), Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I), Arm 4. PEG +RBV + BOC for 48 Wks (Part I), Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I), Arm 6. PEG + RBV + BOC for 48 Wks (Part II), Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I) | Intervention Type: DRUG; Name: ribavirin (low-dose); Assigned to Arm(s): Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II)
D: Arm Label: Genotype 2 treatment-naive; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: Genotype 2/3 treatment-experienced; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: Genotype 1/3/4 treatment-naive; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Genotype 1/3/4 treatment-naive, Genotype 2 treatment-naive, Genotype 2/3 treatment-experienced | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Genotype 1/3/4 treatment-naive, Genotype 2 treatment-naive, Genotype 2/3 treatment-experienced

Answer: D